Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages

Yaxin Chen1†, Yanzhuo Liu2†, Yang Wang3, Xuewei Chen4, Chenlong Wang5, Xuehan Chen3, Xi Yuan3, Lilong Liu3, Jing Yang3* and Xiaoyang Zhou1*

Abstract

**Background:** Immune checkpoint inhibitor-related cardiotoxicity is one of the most lethal adverse effects, and thus, the identification of underlying mechanisms for developing strategies to overcome it has clinical importance. This study aimed to investigate whether microbiota-host interactions contribute to PD-1/PD-L1 inhibitor-related cardiotoxicity.

**Methods:** A mouse model of immune checkpoint inhibitor-related cardiotoxicity was constructed by PD-1/PD-L1 inhibitor BMS-1 (5 and 10 mg/kg), and cardiomyocyte apoptosis and cardiotoxicity were determined by hematoxylin and eosin, Masson's trichrome and TUNEL assays. 16S rRNA sequencing was used to define the gut microbiota composition. Gut microbiota metabolites short-chain fatty acids (SCFAs) were determined by HPLC. The serum levels of myocardial enzymes (creatine kinase, aspartate transaminase, creatine kinase-MB and lactate dehydrogenase) and the production of M1 factors (TNF-α and IL-1β) were measured by ELISA. The colonic macrophage phenotype was measured by mmunofluorescence and qPCR. The expression of Claudin-1, Occludin, ZO-1 and p-p65 was measured by western blot. The gene expression of peroxisome proliferator-activated receptor α (PPARα) and cytochrome P450 (CYP) 4X1 was determined using qPCR. Statistical analyses were performed using Student’s t-test for two-group comparisons, and one-way ANOVA followed by Student–Newman–Keul test for multiple-group comparisons.

**Results:** We observed intestinal barrier injury and gut microbiota dysbiosis characterized by Prevotellaceae and Rikenellaceae genus depletion and *Escherichia-Shigella* and *Ruminococcaceae* genus enrichment, accompanied by low butyrate production and M1-like polarization of colonic macrophages in BMS-1 (5 and 10 mg/kg)-induced cardiotoxicity. Fecal microbiota transplantation mirrored the effect of BMS-1 on cardiomyocyte apoptosis and cardiotoxicity, while macrophage depletion and neutralization of TNF-α and IL-1β greatly attenuated BMS-1-induced cardiotoxicity. Importantly, *Prevotella loescheii* recolonization and butyrate supplementation alleviated PD-1/PD-L1 inhibitor-related cardiotoxicity.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) have achieved great clinical success in antitumor therapy [1]. However, PD-1/PD-L1 inhibitors induce a wide spectrum of immune-related adverse events (irAEs), with cardiotoxicity being the most lethal adverse effect [2]. ICI-related cardiotoxicity events occur in different forms, including myocarditis, cardiomyopathy and myocardial fibrosis, and myocarditis with evidence of cardiomyocyte apoptosis is one of the most important clinical and pathological features [3, 4]. Multiple mechanisms of irAEs, including cardiotoxicity, have been proposed, especially proinflammatory cytokine release in addition to direct cytotoxic activity by T cells on nontumor cells [5, 6]. Therefore, it is essential to minimize systemic inflammation to overcome PD-1/PD-L1 inhibitor-induced cardiotoxicity, particularly myocarditis.

Alterations in gut microbiota play an important role in inflammatory response in cardiovascular disease [7, 8]. Gut microbiota metabolizes short-chain fatty acids (SCFAs), such as butyrate, have anti-inflammatory properties [9]. Butyrate and its derivative phenylalanine-butyrate can protect against doxorubicin (DOX)-induced cardiotoxicity [10, 11], and a decreased abundance of microbes with the capacity to produce butyrate has been identified in the pathogenesis of DOX-related cardiotoxicity [10]. Manipulation of gut microbiota by fecal transplantation improves the efficacy of PD-1/PD-L1 inhibitors [12]. However, whether manipulation of gut microbiota and its metabolites, including butyrate, prevents PD-1/PD-L1 inhibitor-induced cardiomyocyte apoptosis and cardiotoxicity is still not clear.

Macrophages are primary producers of inflammatory mediators during autoimmune and autoinflammatory diseases [13]. A previous study showed that a PD-1 inhibitor induces cardiac injury through polarization of cardiac macrophages to an M1-like phenotype [6]. Our recent study showed that colonic macrophages, one of the most numerous leukocytes in colon, contribute to multilayered carbon nanotube-exacerbated cardiotoxicity [14]. Conversely, flavonoid glabridin prevents DOX-induced acute cardiotoxicity by polarizing colonic macrophages away from the M1-like phenotype via gut microbiota-derived butyrate [10]. Cytochrome P450 (CYP) 4X1, an orphan CYP protein, metabolizes anandamide (N-arachidonoyl-ethanolamine, AEA) to 14,15-epoxyeicosatrienoic acids-ethanolamide (14,15-EET-EA) [15]. Our previous study showed that CYP4X1 inhibition repolarizes tumor-associated macrophages to an M1 phenotype and upregulates M1-like factors TNF-α and IL-1β [15]. However, whether CYP4X1 and colonic macrophage-derived M1-like factors TNF-α and IL-1β contribute to PD-1/PD-L1 inhibitor-related cardiotoxicity has not been explored.

Numerous immunotherapy agents, including nivolumab and pembrolizumab, have been approved by the Food and Drug Administration (FDA) for cancer treatment [16]. BMS-1, a small-molecule inhibitor of PD-1/PD-L1 interaction, possesses effects similar to anti-PD-1/PD-L1 antibodies, suggesting that it could be an alternative to antibodies used in immunotherapy [17]. In addition, compared with antibodies drugs, small-molecule PD-1/PD-L1 inhibitors offer inherent advantages in terms of their pharmacokinetics and druggability, thereby achieving better therapeutic effects and providing a promising perspective [18].

In this study, the effects of gut microbiota dysbiosis and low butyrate production on PD-1/PD-L1 inhibitor-related cardiotoxicity were first measured in mice with melanoma. We then investigated whether M1-like colonic macrophage-derived factors IL-1β and TNF-α contribute to PD-1/PD-L1 inhibitor-induced cardiomyocyte apoptosis and cardiotoxicity. Finally, we investigated whether gut microbiota dysbiosis upregulates proinflammatory factors TNF-α and IL-1β in colonic macrophages through downregulation of butyrate-CYP4X1 axis. Our results identified a novel mechanism of action of PD-1/PD-L1 inhibitor-related cardiotoxicity, and may provide a potential therapeutic target.

Methods

Chemicals and reagents

BMS-1 (HY-19991) and sodium butyrate (HY-B0350A) were purchased from MedChemExpress (Monmouth Junction, New Jersey, USA). Lipopolysaccharide (LPS) (L2630) was purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Methionine-enriched charcoal-stripped F-12 medium was purchased from Gibco, and human colorectal cancer cell L2630 was purchased from Sigma-Aldrich.
MO, United States). Peroxisome proliferator-activated receptor α (PPARα) antagonist GW6471 (T8486) was purchased from Tocris (Bristol, UK). 14,15-EET-EA (10008599) was purchased from Cayman Chemicals (Ann Arbor, MI). Antibodies against HS-associated protein X-1 (HAX-1) (ab78939), cleaved caspase 3 (ab13847), cleaved caspase 9 (ab202068), CD68 (ab125212), iNOS (ab178945), CD206 (ab64693), CYP4X1 (ab74810) and β-actin (ab8226) were purchased from Abcam (Cambridge, MA, United States). Anti-colony-stimulating factor-1 (CSF-1) (BE0204), anti-TNF-α (BP0058) and anti-IL-1β (BE0246) antibodies were purchased from BioXCell (West Lebanon, NH, United States). Antibodies against B-cell lymphoma protein 2-associated X (Bax) (2772), B-cell lymphoma-2 (Bcl-2) (3498), p65 (8242) and phosphor-p65 (3033) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibody against PPARα (15540–1-AP) was purchased from Proteintech (Chicago, Illinois, USA). Antibodies against Claudin-1 (BM5140), Occludin (A01246–2) and proliferating cell nuclear antigen (PCNA) (BM3888) were purchased from Wuhan Boster Biological Technology (Wuhan, China). Anti-ZO-1 antibody (GB111402) was purchased from Wuhan Servicebio Biological (Wuhan, China).

Cell cultures
Mouse melanoma B16F10 cells and the macrophage cell line RAW264.7 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), and cultured in Dulbecco's modified Eagle's medium containing 10% heat-inactivated fetal calf serum (FCS, 10100147, Gibco, Carlsbad, CA, USA) and 100 U/ml penicillin and streptomycin (10378016, Invitrogen, Carlsbad, CA, USA). Mouse cardiomyocyte HL-1 (SCC065) was purchased from Sigma–Aldrich (St. Louis, MO, USA), and cultured in Claycomb medium (51800C, Sigma–Aldrich) containing 10% heat-inactivated fetal calf serum and 100 U/ml penicillin and streptomycin. All cells were cultured at 37°C in a humidified 5% CO2 atmosphere.

Animals and treatments
C57BL/6 mice (male, 6–8 weeks old) were purchased from the Centers for Disease Control and Prevention (Hubei, China). Male Cyp4x1 knockout (Cyp4x1<sup>−/−</sup>) mice were generated using the CRISPR/Cas9 system on a C57BL/6 background (Bioray Laboratory, Shanghai, China). The mice were acclimatized for 1 week to adapt to the new environment before the experiment. The animals were housed in polypropylene cages with food and water available ad libitum. The room temperature was maintained at 18–22°C under a 12 h light/12 h dark cycle. The mice were caged individually to avoid any effects of cohousing on microbiota composition.

For PD-1/PD-L1 inhibitor BMS-1 treatment experiment, B16F10-luciferase cells (5 × 10<sup>6</sup>) were injected into the right flank of the C57BL/6 mice. When the tumors reached a size of approximately 100 mm<sup>3</sup>, the mice were randomly divided into three groups (n = 10): BMS-1 (5 and 10 mg/kg) and control groups. The mice were intraperitoneally injected with BMS-1 (0, 5 and 10 mg/kg) every 2 days for a total of 6 times. Body weight and food intake were measured per animal. Tumor growth was measured by a luciferase-based noninvasive bioluminescence imaging system (In-Vivo Xtreme II, Bruker). The melanoma images were analyzed by quantification of total photon flux of each tumor using Molecular Imaging Software. The mice were euthanized 24 h after the last injection of BMS-1, and then peripheral blood, tumors, colonic and cardiac tissues were collected and analyzed. The mice in the control group (n = 10) were intraperitoneally injected with an equivalent volume of phosphate buffer saline (PBS). The doses (5 and 10 mg/kg) of BMS-1 used in this study were based on a published study [19] and our preliminary experiments.

Fecal microbiota transplantation (FMT) was performed as described [14]. Briefly, the mice were pretreated with a cocktail of broad-spectrum antibiotics (Abx), including 0.5 g/L vancomycin, 0.5 g/L neomycin sulfate and 0.5 g/L primaxin in the drinking water for 2 weeks to clear the gut microbiota. Next, the mice were orally administered a fecal suspension (300 μL per mouse) derived from BMS-1 (5 and 10 mg/kg) or PBS-treated mice every 2 days for a total of 6 times.

The bacterial colonization or exogenous metabolite supplementation experiments were performed as previously described [10]. Briefly, a cocktail of lyophilized Prevotella loescheii (P. loescheii) (ATCC 15930) was resuspended in phosphate-buffered saline at 5 × 10<sup>9</sup> colony forming units (CFUs)/ml. The mice (n = 10) were orally administered with sodium butyrate (1 g/kg/day) or cocktail (200 μL/mouse, every 2 days) for 1 week. The dose of sodium butyrate used in the present study was based on published study [10] and our preliminary experiments.

Macrophage depletion experiments were performed with an anti-CSF-1 antibody as previously described [20]. Briefly, the mice (n = 10) were intraperitoneally administered with 50 mg/kg anti-CSF-1 antibody 24 h before BMS-1 injection, followed by repeated injections of 25 mg/kg anti-CSF-1 antibody every 5 days.

IL-1β and TNF-α neutralization experiments were performed as previously described [14]. Briefly, the mice (n = 10) were administered intraperitoneally with anti-TNF-α antibody (100 μg), anti-IL-1β antibody (100 μg) or their combination every 2 days for a total of 3 times during the PD-1/PD-L1 inhibitor treatment.
The control mice received 100 μg IgG as an isotype control [21], and no IgG-related side effects were observed during the experiment.

**Fecal microbiota analysis by 16S rRNA sequencing**

Fecal microbiota analysis by 16S rRNA sequencing was based on a previous description [14]. Briefly, fresh stool pellets from the PD-1/PD-L1 inhibitor BMS-1 (5 and 10 mg/kg) and PBS-treated mice were obtained before the mice were euthanized, and immediately frozen in liquid nitrogen. Genomic DNA from fecal samples (50–100 mg) was extracted using the TIANamp stool DNA kit (TIANGEN Biotech Co., Ltd., Beijing, China) according to the manufacturer’s instructions. The concentration and purity of the extracted bacterial DNA were measured using a NanoDrop 2000C spectrophotometer (Thermo Fisher Scientific, Waltham, USA). The 16S rRNA gene in the fecal DNA samples was amplified by polymerase chain reaction (PCR) targeting the hypervariable V3-V4 region of the 16S rRNA gene with primers 338-F (5′-GTGCCCAGCMGCCGCGGTAA-3′) and 806-R (5′-GGACTACHVGGGWTWTCTAAT-3′). Sequencing was performed by an Illumina MiSeq PE300 system (OE Biotech Co., Ltd.). As an added quality control measure, the software package MacQIIME (version 1.9.1) pipeline was used to filter out and discard poor-quality reads using the default settings [20]. The sequences were further clustered into operational taxonomic units or phylotypes (OTUs) at 97% identity using QIIME and cdhit. OTUs were assigned to the closest taxonomic neighbors and relative bacterial species using Seqmatch and Blastall. Principle coordinate analysis (PCoA) projections were visualized using Emperor 0.9.4.

**Analysis of short-chain fatty acids in the feces**

SCFAs in the feces from BMS-1 (5 and 10 mg/kg) and control groups were analyzed by high-performance liquid chromatography (HPLC) based on a previous description [10]. Then, 400 μL of HCl was added to the fecal homogenates to preserve the volatile SCFAs and they were centrifuged at 14,000 g to evenly suspend the fecal mass. The resulting supernatants were then passed through a 0.22 μm syringe filter to remove bacterial cells and any debris. SCFA analyses were performed using an Agilent Technologies 1290 Infinity II and a 300 SB C18 column (1.8 μm, 2.1 × 100 mm) with a guard column, and 0.01 M H2SO4 was used as the mobile phase. SCFAs were identified by comparing sample peak retention times to a standard mixture of acetate, propionate, butyrate, valerate, and hexanoate.

**Isolation of peritoneal and colonic macrophages**

Peritoneal macrophages (PNMs) were isolated and grown as described previously [14]. Briefly, the mice treated with the PD-1/PD-L1 inhibitor BMS-1 (10 mg/kg) were sacrificed, and 5 mL of heat-inactivated PBS was injected into the abdomen. Then, the abdomen was massaged gently for 3 min. The peritoneal fluid was drawn back. After centrifugation at 1500 g for 10 min, the cell pellets were suspended in DMEM (supplemented with 10% (v/v) bovine calf serum, 100 U/mL penicillin and 100 U/mL streptomycin) and then allowed to adhere for 3 h at 37 °C in a humidified incubator containing 5% CO2. After 4 h of incubation, non-adherent cells were removed by washing twice with PBS, and then freshly prepared medium was added.

Colonic macrophages were isolated by flow cytometry as previously described [20]. Briefly, colonic tissues from BMS-1 (5 and 10 mg/kg), *Cypr4x1−/−*, *P. loescheii* butyrate and control groups were cut into 0.5 cm pieces, and then incubated with 0.25% trypsin at 37 °C for 30 min. The cell suspension was passed through a 100 μm strainer and stained with PerCP/Cy5.5-conjugated anti-CD11c antibody (ab111469, Abcam, Cambridge, MA, United States) and PE-conjugated anti-F4/80 antibody (ab105155, Abcam, Cambridge, MA, United States) and PE-conjugated anti-CD11b antibody (ab269361, Abcam, Cambridge, MA, United States). The stained cells were then sorted using a...
Fig. 1 (See legend on previous page.)
Fig. 2  BMS-1 induces intestinal barrier injury in mice with melanoma. In the B16F10 melanoma model, the mice were intraperitoneally administered with the PD-1/PD-L1 inhibitor BMS-1 (0, 5 and 10 mg/kg) every 2 days for 6 times (n = 10).  

A. Representative images of hematoxylin and eosin (HE) staining of colonic tissues and corresponding quantification analysis. Scale bars, 100 μm.  

B. Representative images of Alcian blue-periodic acid-Schiff (ABPAS) of colonic tissues and corresponding quantification analysis. Scale bars, 100 μm.  

C. Representative images of proliferating cell nuclear antigen (PCNA) and corresponding quantification analysis. Scale bars, 100 μm.  

D. Representative western blot images of Claudin-1, Occludin and ZO-1 in colonic tissues and corresponding quantification analysis.  

E. Representative images of laser Doppler analysis and corresponding quantification analysis. Scale bar, 2 mm. The values are presented as the mean ± standard error of the mean. *P < 0.05, **P < 0.01 vs. control.
FACS Aria Cell Sorter (BD Biosciences). The purity of the colonic macrophage was >95%. Freshly isolated colonic macrophages were incubated in 12-well plates at 80 to 90% confluence, and resupplied with serum-free RPMI 1640 media for 24 h. The supernatant and colonic macrophages were collected for further experiments.

Transfection with PPARα siRNA
The PPARα siRNA transfection experiment was performed as previously described [22]. siRNA targeting PPARα (sc-36,308) was obtained from Santa Cruz Biotech, Inc. (Dallas, TX, USA), and transfection was performed using Santa Cruz’s siRNA transfection reagent (sc-29,528), transfection medium (sc-36,868), and dilution buffer (sc-29,527) according to manufacturer’s instructions. Briefly, PNMS and RAW264.7 cells were seeded into six-well plates in 2 mL medium. For each well, 0.8 mL transfection mixture containing 200 nmol of PPARα siRNA was added and incubated at 37 °C for 7 h. After incubation, the cells were maintained with 1 mL of normal growth medium without removing siRNA mixture at 37 °C for 24 h. Then, the medium was replaced with fresh normal growth medium and the cells were incubated for an additional 24 h. After preparation of the cell lysates, depletion of PPARα expression was confirmed by qPCR and western blot analysis.

Preparation of conditioned media (CM)
The CM was prepared as previously described [15]. In brief, PNMS and RAW264.7 cells were stimulated with LPS (1 μM), butyrate (5 mM), GW6471 (25 μM), 14,15-EET-EA (20 mg/ml), PPARα siRNA or vehicle (DMSO or control siRNA) for 12 h. The culture supernatants were harvested, and then subjected to centrifugation through an Amicon Ultra4 filter to remove any traces of butyrate, GW6471, 14,15-EET-EA or PPARα siRNA. The retentate was collected as CM.

Laser Doppler analysis of mesenteric perfusion
The mesenteric perfusion was measured by laser Doppler analysis as previously described [23]. Briefly, the mice treated with the PD-1/PD-L1 inhibitor BMS-1 (0, 5 and 10 mg/kg) as described above were anesthetized with 3% or 0.6% pentobarbital and placed on a heating pad (37 °C). An incision in the abdomen was made, and the distal ileum and its accompanying mesentery were exposed for in vivo observation of the microcirculation. The mesenteric vessels were carefully separated, and Krebs-Henseleit solution (37 °C) saturated with a mixture of gases (95% N2 and 5% CO2) was used to maintain the mesentery warm and moist. Mesenteric perfusion of each animal was blindly measured using a laser Doppler analyzer with a CCD camera (SXX40c, Baumer, Germany). The mesenteric perfusion in arbitrary perfusion units was monitored graphically. The mice were euthanized after completion of the treatment.

Statistics
Data are presented as mean ± standard error of the mean (SEM). Normal distribution of the data was assessed by the Kolmogorov–Smirnov test. For normally distributed data, Student’s t–test was used for two-group comparisons, and one-way ANOVA followed by Student–Newman–Keul’s test was used for multiple-group comparisons [10]. The statistical significance of changes over time was evaluated by one-way repeated-measures ANOVA followed by Bonferroni’s post hoc test. The data of microbiome abundance were analyzed by the nonparametric Mann–Whitney U test corrected for multiple comparisons. The predominance of bacterial communities between groups was analyzed using the linear discriminant analysis (LDA) effect size (LEfSe) (LDA score (log10) = 2.0 as the cutoff value) [24]. Statistical analysis was carried out by GraphPad Prism 8.0.2 software [20], and statistical significance was defined as P < 0.05.
Fig. 3 (See legend on previous page.)
Results

BMS-1 induces cardiomyocyte apoptosis and cardiotoxicity in mice with melanoma

The food intake and body weights of all of the mice were monitored throughout the study. The food intake by the mice treated with the PD-1/PD-L1 inhibitor BMS-1 (5 and 10 mg/kg) showed a decreasing trend compared with the control, although there was no significant difference among the three groups (Fig. 1A). BMS-1 (5 and 10 mg/kg) decreased the weight but increased the ratio of heart/body weight of the mice (Fig. 1B). Cardiotoxicity is defined as heart injury (functional or structural) related to cancer treatment [25]. A previous study showed that brain natriuretic peptide (BNP), an indicator of cardiac malfunction, is significantly elevated in ICI-associated cardiotoxicity [26]. As expected, BMS-1 (10 mg/kg) significantly increased the BNP level (Fig. 1C). Similar results were obtained in the activities of myocardial enzymes including CK-MB, AST, CK and LDH in the peripheral blood of the mice treated with BMS-1 (Fig. 1D). In addition, BMS-1 (10 mg/kg) significantly decreased the levels of antiapoptotic proteins including HAX-1 and Bcl-2, but it increased the levels of pro-apoptotic proteins including Bax, cleaved caspase 3 and cleaved caspase 9 (Fig. 1E). BMS-1 (5 and 10 mg/kg) also increased inflammatory infiltration, interstitial fibrosis and the number of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cardiomyocytes in the cardiac tissues compared with the control (Fig. 1F-H). Similar to previous studies [17], BMS-1 (5 and 10 mg/kg) inhibited melanoma growth, as demonstrated by a decreased tumor weight and luciferase intensity (Fig. 1I and J). These data suggested that the PD-1/ PD-L1 inhibitor BMS-1 induces cardiomyocyte apoptosis and cardiotoxicity in mice with melanoma.

BMS-1 induces intestinal mucosal barrier injury in mice with melanoma

Intestinal barrier dysfunction including mechanical barrier (intestinal mucosal epithelia) and biological barrier (gut microbiota) injury contributes to impaired cardiac function [27]. Therefore, the colonic mucosal integrity was evaluated. As shown in Fig. 2A-D, BMS-1 (5 and 10 mg/kg) decreased the villus height and the number of goblet cells along with the number of proliferating cell nuclear antigen (PCNA)-positive cells, and it downregulated the expression of tight junction proteins Claudin-1, Occludin and ZO-1 in the colonic tissues compared with the control. Next, we determined the mesenteric perfusion scores, and found that BMS-1 (5 and 10 mg/kg) decreased the mesenteric perfusion (Fig. 2E). These data suggested that BMS-1 induces intestinal mucosal barrier injury in mice with melanoma.

Gut microbiota dysbiosis contributes to PD-1/PD-L1 inhibitor-related cardiotoxicity

Next, we sequenced the bacterial 16S rRNA in the feces to assess the intestinal biological barrier. The rarefaction curves of the bacterial community reached a saturation plateau, indicating that the sequencing depth was sufficient to represent the majority of microbe species (Fig. S1). Although BMS-1 (5 and 10 mg/kg) did not significantly influence the total fecal bacterial load or category (Fig. 3A), microbial beta diversity analysis based on principal coordinate analysis showed an obvious dissimilarity in gut microbiota constitution, especially between the BMS-1 (10 mg/kg) and control groups (Fig. 3B). This was further supported by microbial alpha diversity analysis, as calculated by decreased the Shannon index, without influencing the Chao index and Sobs index (Fig. 3C and D). Figure 3E showed that BMS-1 significantly altered the abundance of bacterial phyla. The ratio between Firmicutes and Bacteroidetes, a marker of gut dysbiosis [10], was significantly increased by BMS-1 (5 and 10 mg/kg) (Fig. 3F). LEfSe was used to define the differentially expressed bacteria (Fig. 3G). At the phylum level, BMS-1 (5 and 10 mg/kg) significantly depleted Bacteroidota. Conversely, the abundance of Firmicutes and Proteobacteria was significantly increased in BMS-1 (10 mg/kg)-treated mice compared with the control. At the order level, BMS-1 dose (5 and 10 mg/kg)-dependently depleted Bacteroidales and Christensenellales but enriched Enterobacteria. At the genus level, a depletion of Prevotellaceae and Rikenellaceae genus and an enrichment of Escherichia-Shigella was observed in BMS-1 (10 mg/kg)-treated mice compared with the control. The
Fig. 4 (See legend on previous page.)
abundance of *Ruminococcaceae* genus was significantly increased in BMS-1 (5 mg/kg)-treated mice as compared with the control, although there was no significant difference between the BMS-1 (10 mg/kg) and control groups (Fig. 3H). To test the role of the gut microbiota in BMS-1-induced cardiotoxicity, we performed an FMT experiment in which gut microbiota-depleted mice were reconstituted with the gut microbiota of BMS-1 (5, 10 mg/kg)-treated mice (Fig. 3I). Unexpectedly, FMT from BMS-1-treated mice significantly induced the leakage of myocardial enzymes (CK-MB, AST, CK and LDH) and the apoptosis of cardiomyocytes (Fig. 3 and K). These data suggested that gut microbiota dysbiosis contributes to PD-1/PD-L1 inhibitor-related cardiotoxicity.

**P. loescheii** colonization and butyrate supplementation alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity

KEGG pathway analysis was performed to detect the relative abundances of functional genes in gut microbiota. Remarkably, the fatty acid synthesis pathway was predominantly downregulated in BMS-1 (10 mg/kg)-treated mice compared with the control (Fig. 4A). Gut microbiota metabolites SCFAs mediate anti-inflammatory effects in numerous inflammatory diseases, and low microbial SCFA production is linked to heart failure [10]. Thus, we measured SCFAs in the feces from BMS-1 and control mice, and found that BMS-1 (5 and 10 mg/kg) significantly decreased butyrate level, while acetate, propionate, valerate and hexanote remained unchanged (Fig. 4B). Next, we supplied *P. loescheii*, one of the main SCFA-producing strain in *Prevotellaceae* [28], or butyrate to BMS-1 (10 mg/kg)-treated mice (Fig. 4C), and the efficacy of *P. loescheii* colonization was confirmed by increased levels of *P. loescheii* (Fig. 4D) and butyrate in the feces (Fig. 4E). Obviously, *P. loescheii* colonization and butyrate supplementation attenuated BMS-1-induced myocardial enzyme leakage and myocardial apoptosis (Fig. 4F and G). These data suggested that *P. loescheii* colonization and butyrate supplementation alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity.

**M1-like colonic macrophages and their factors IL-1β and TNF-α contribute to PD-1/PD-L1 inhibitor-related cardiotoxicity**

A previous study showed that a PD-1 inhibitor induces M1-like polarization of cardiac macrophages [6]. We found that BMS-1 (5 and 10 mg/kg) significantly increased the number of M1-like (CD68<sup>+</sup>iNOS<sup>+</sup>) cells and upregulated M1 genes (iNOS and CXCL9), but decreased the number of M2-like (CD68<sup>+</sup>CD206<sup>+</sup>) cells and downregulated M2 genes (CD206 and Arg-1) (Fig. 5A-D). In addition, BMS-1 significantly increased the levels of IL-1β and TNF-α but not TGF-β and IL-10 in colonic macrophages (Fig. 5E). To determine whether BMS-1-induced cardiotoxicity through the alteration of the colonic macrophage phenotype, we depleted colonic macrophages with an anti-CSF-1 antibody (IgG as a control) (Fig. 5F). As shown in Fig. 5G and H, anti-CSF-1 antibody significantly decreased the levels of myocardial enzymes (CK, LDH, CK-MB and AST) in peripheral blood and the number of TUNEL-positive cells in the cardiac tissues from the mice treated with BMS-1 (10 mg/kg). Next, we used antibodies against IL-1β and TNF-α to block their effects (Fig. 5I) and found that the anti-IL-1β or anti-TNF-α antibody partly abolished BMS-1-induced cardiotoxicity, as shown by decreased interstitial fibrosis and myocardial apoptosis in cardiac tissues. Importantly, a combined block of IL-1β and TNF-α showed better efficacy than a single block in attenuating PD-1/PD-L1 inhibitor-related cardiotoxicity (Fig. 5 and K). These data suggested that the M1-like colonic macrophage-derived factors IL-1β and TNF-α contribute to PD-1/PD-L1 inhibitor-induced cardiomyocyte apoptosis and cardiotoxicity.

**P. loescheii** colonization and butyrate supplementation downregulate IL-1β and TNF-α in colonic macrophages

Our previous study showed that decreased butyrate level in feces reprogrammed colonic macrophages to a proinflammatory phenotype in DOX-induced cardiotoxicity [10]. Here, we supplied butyrate or *P. loescheii*...
Fig. 5 (See legend on previous page.)
to BMS-1 (10 mg/kg)-treated mice, and found that *P. loescheii* colonization and butyrate supplementation inhibited the BMS-1-induced increase in the number of M1-like (CD68^+iNOS^+) cells and decrease in the number of M2-like (CD68^+CD206^+) cells in the colonic tissues (Fig. 6A). *P. loescheii* colonization and butyrate supplementation downregulated the mRNA expression of M1 genes (iNOS and CXCL9), but upregulated the expression of M2 genes (CD206 and Arg-1) (Fig. 6B). In addition, we observed similar alterations in the levels of M1-like factors (IL-1β and TNF-α) and M2-like factors (TGF-β and IL-10) in colonic macrophages (Fig. 6C). These data suggested that *P. loescheii* colonization and butyrate supplementation prevent M1-like polarization of colonic macrophages and the production of proinflammatory factors IL-1β and TNF-α in PD-1/PD-L1 inhibitor-related cardiotoxicity.

**Butyrate prevents NF-κB-mediated M1-like polarization and cardiomyocyte apoptosis via PPARα activation**

A previous study showed that PPARα, a ligand of butyrate [29], negatively regulates M1 macrophage polarization by interacting with p65 to abolish its binding to the NF-κB response element [30]. We found that BMS-1 (5 and 10 mg/kg) significantly decreased the expression of PPARα in colonic macrophages (Fig. 7A). To test the role of PPARα in colonic macrophage polarization and thus cardiomyocyte apoptosis, we cocultured HL-1 cardiomyocytes with CM from PNMS or RAW264.7 cells treated with LPS plus butyrate and GW6471 (PPARα antagonist). The efficacy of GW6471 in inhibiting PPARα expression was determined by western blot and qPCR (Fig. 7B). As shown in Fig. 7C-F, butyrate prevented LPS-induced upregulation of p-p65, TNF-α and IL-1β in PNMS and RAW264.7 cells,

---

**Fig. 6** *P. loescheii* colonization and butyrate supplementation downregulate IL-1β and TNF-α in colonic macrophages. In the B16F10 melanoma model, the C57BL/6 mice were orally administrated with *Prevotellaceae loescheii* (*P. loescheii*) (1 × 10^8^ CFU/mouse/every 2 days) or sodium butyrate (1 g/kg) for 1 week during BMS-1 (10 mg/kg)-treatment (*n* = 10). A Representative images of immunostaining analysis of CD68^+iNOS^+ and CD68^+CD206^+ cells in colonic tissues and corresponding quantitative analysis. Scale bars, 20 μm. B M1 marker (iNOS and CXCL9) and M2 marker (CD206 and Arg-1) in colonic macrophages were measured by qPCR. C The M1 factors (IL-1β and TNF-α) and M2 factors (TGF-β and IL-10) in colonic macrophages were determined by ELISA. The values are presented as the mean ± standard error of the mean. *P < 0.05, **P < 0.01 vs. BMS-1
Butyrate prevents NF-κB-mediated M1-like polarization and cardiomyocyte apoptosis via PPARα activation. In the B16F10 melanoma model, the mice were intraperitoneally administered with the PD-1/PD-L1 inhibitor BMS-1 (0, 5 and 10 mg/kg) every 2 days for 6 times (n = 10).

**A** Immunostaining analysis of the CD68+PPARα+ cells in colonic tissues. Scale bars, 20 μm.

**B** HL-1 cardiomyocytes were co-cultured with the conditioned medium (CM) from peritoneal macrophages (PNMS) and RAW264.7 cells treated with the LPS plus butyrate and GW6471. The efficacy of GW6471 to inhibit PPARα expression was determined by western blot and qPCR (n = 5).

**C** Representative western blot images of p65 and p-p65 in PNMS and RAW264.7 cells and corresponding quantification analysis. E1 M1 factors (IL-1β and TNF-α) in PNMS and RAW264.7 cells were determined by ELISA. F Representative images of TUNEL assay of HL-1 cardiomyocytes and corresponding quantification analysis. Scale bars, 50 μm.

The values are presented as the mean ± standard error of the mean. *P < 0.05, **P < 0.01 vs. control or LPS. #P < 0.05, ##P < 0.01 vs. LPS + butyrate.
that PPARα activates human CYP4X1 gene transcription [31]. We found that PPARα siRNA downregulated PPARα mRNA and protein expression in colonic macrophages (Fig. 9G). Exogenous supplementation with 14,15-EET-EA significantly attenuated the decrease in PPARα expression and the increase in IL-1β and TNF-α production in PNMS, and thus reversed the cardiomyocyte apoptosis induced by BMS-1 (Fig. 9H-K). These data suggested that downregulation of CYP4X1 by a PD-1/PD-L1 inhibitor inactivates PPARα and forms a positive feedback loop in colonic macrophages.

Discussion

In the present study, we provide the first direct evidence that PD-1/PD-L1 inhibitors induce cardiomyocyte apoptosis and cardiotoxicity in a gut microbiota-dependent manner, and that P. loescheii colonization and butyrate supplementation play a protective role in PD-1/PD-L1 inhibitor-related cardiotoxicity. Importantly, we demonstrated for the first time that inhibition of the PPARα and CYP4X1–14,15EET-EA positive feedback loop promoted M1-like polarization of colonic macrophages and the production of TNF-α and IL-1β. Our results identify a novel mechanism of action of PD-1/PD-L1 inhibitor-related cardiotoxicity (Fig. 10), and manipulating the gut microbiota P. loescheii and its metabolite butyrate to modulate the PPARα-CYP4X1 axis in colonic macrophages could reduce the risk of cardiotoxicity following anti-PD-1/PD-L1 treatment.

Gut microbiota, including Prevotellaceae, Rikenellaceae and Ruminococcaceae and their metabolites SCFAs play important roles in intestinal barrier integrity and intestinal homeostasis [32]. Rikenellaceae, which belongs to the Bacteroidetes phylum, is correlated with resistance to CTLA-4 inhibitor-related colitis [33], and a reduction in butyrate-producing taxa promotes systemic inflammation and atherosclerosis [34]. In contrast, the expansion of Ruminococcaceae and decreased the number of TUNEL-positive HL-1 cardiomyocytes. In contrast, the PPARα antagonist GW6471 abolished the protective effect of butyrate. Similar results from the PPARα siRNA silencing experiment confirmed that butyrate prevented LPS-induced M1-like polarization and cardiomyocyte apoptosis in a PPARα-dependent manner (Fig. 8A-F). In addition, we cocultured HL-1 cardiomyocytes with CM from PNMS or RAW264.7 cells treated with LPS plus anti-IL-1β or anti-TNF-α antibody, and found that anti-IL-1β or anti-TNF-α antibody partly abolished LPS-induced cardiotoxicity, as demonstrated by the decreased levels of myocardial enzymes and the number of TUNEL-positive cardiomyocytes. Importantly, a combined block of IL-1β and TNF-α showed better efficacy than a single block (Fig. 8G-I). These data suggested that butyrate prevents NF-kB-mediated M1-like polarization and cardiomyocyte apoptosis via PPARα activation.

Downregulation of CYP4X1 by a PD-1/PD-L1 inhibitor inactivates PPARα and forms a positive feedback loop in colonic macrophages

Our recent study showed that CYP4X1 inhibition polarizes TAMs to an M1-like phenotype [15]. Thus, we measured CYP4X1 expression in colonic macrophages. As shown in Fig. 9A, BMS-1 (5 and 10 mg/kg) significantly decreased CYP4X1 expression in colonic macrophages. Moreover, the catalytic production of 14,15-EET-EA derived from CYP4X1 was significantly decreased in colonic macrophages from mice treated with BMS-1 (5 and 10 mg/kg) compared with the control (Fig. 9B). Next, the WT and Cyp4x1−/− mice were treated with BMS-1 (10 mg/kg). As shown in Fig. 9C and D, a decrease in 14,15-EET-EA production and an increase in TNF-α and IL-1β secretion were observed in colonic macrophages from Cyp4x1−/− mice compared with those from WT mice. In addition, we observed more TUNEL-positive cardiomyocytes and higher serum levels of myocardial enzymes (CK, LDH, CK-MB and AST) in Cyp4x1−/− mice (Fig. 9E and F). A previous study showed that PPARα activates human CYP4X1 gene transcription [31]. We found that PPARα siRNA downregulated CYP4X1 (Fig. S2), and in turn, Cyp4x1 knockout downregulated PPARα mRNA and protein expression in colonic macrophages (Fig. 9G).
Fig. 8 (See legend on previous page.)
Fig. 9 Downregulation of CYP4X1 by a PD-1/PD-L1 inhibitor inactivates PPARα and forms a positive feedback loop in colonic macrophages. In the B16F10 melanoma model, the mice were intraperitoneally administered with the PD-1/PD-L1 inhibitor BMS-1 (0, 5 and 10 mg/kg) every 2 days for 6 times (n = 10). A CYP4X1 mRNA and protein levels in colonic macrophages. B The level of 14,15-EET-EA in colonic macrophages was determined by liquid chromatography tandem-mass spectrometry (LC-MS/MS). C In the B16F10 melanoma model, the wild type (WT) and Cyp4x1 knockout mice (Cyp4x1−/−) mice were intraperitoneally administered with BMS-1 (10 mg/kg) every two days for 6 times (n = 10). The production of 14,15-EET-EA in colonic macrophages was determined by LC-MS/MS. D M1 factors (IL-1β and TNF-α) in colonic macrophages were determined by ELISA. E Representative images of TUNEL assay of cardiac tissues and corresponding quantification analysis. Scale bars, 50 μm. F The serum levels of creatine kinase (CK), lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB) and aspartate transaminase (AST). G PPARα mRNA and protein levels in colonic macrophages. H HL-1 cardiomyocytes were treated with the conditioned medium (CM) from the peritoneal macrophages (PNMS) in the mice treated with PD-1/PD-L1 inhibitor plus 14,15-EET-EA (n = 5). I PPARα mRNA and protein levels in the PNMS. J M1 factors (IL-1β and TNF-α) in the PNMS. K Representative images of TUNEL assay of HL-1 cardiomyocytes and corresponding quantification analysis. Scale bars, 50 μm. The values are presented as the mean ± standard error of the mean. *P < 0.05, **P < 0.01 vs. control, WT or BMS-1.
of Proteobacteria, specifically *Escherichia-Shigella*, has a positive correlation with immunosuppressive drug-induced gastrointestinal toxicity [35]. Here, we observed gut microbiota dysbiosis characterized by depletion of *Prevotellaceae* and *Rikenellaceae* genus, enrichment of *Escherichia-Shigella* and *Ruminococcaceae* genus and low microbial butyrate production in PD-1/PD-L1 inhibitor-induced cardiotoxicity in mice. Importantly, we first demonstrated that a PD-1/PD-L1 inhibitor induced cardiomyocyte apoptosis and cardiotoxicity, at least partly through *P. loescheii* depletion and low butyrate production in gut microbiota. We concluded that in addition to *P. loescheii* depletion and low butyrate production, *Escherichia-Shigella* enrichment and high LPS production might also contribute to PD-1/PD-L1-related cardiotoxicity, and additional experiments are being carried out to investigate this possibility. A previous study showed that enrichment of *Prevotellaceae*, *Rikenellaceae* and *Bacteroides* in the gut microbiota contributes to acute myocardial ischemia in rats [37], and the abundance of *Ruminococcaceae* bacteria is negatively correlated with isoproterenol-induced arterial stiffness [38]. This discrepancy may be due to the differences in the pathological conditions (apoptosis versus arterial stiffness), exogenous toxin (PD-1/PD-L1 inhibitor versus isoproterenol) and the animal models (C57BL/6 mice versus Wistar rats), and future efforts are warranted to clarify these possibilities.

Colonic macrophages provides an active target for potential novel therapies in maintaining homeostasis and resisting inflammation [39]. Macrophages in peritoneal exudate are polarized to an M1 phenotype in PD-1-deficient mice [40]. Our recent study showed that colonic macrophages are polarized to an M1-like phenotype in DOX-induced cardiotoxicity, and reprogramming colonic macrophages away from the M1-like phenotype attenuates DOX-induced acute

![Fig. 10](image)

**Fig. 10** *Prevotellaceae* produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity through the upregulation of PPARα-CYP4X1 axis in colonic macrophages. 14,15-EET-EA, 14,15-epoxyeicosatetraenoic acid ethanolamide; CYP4X1, cytochrome P450 4X1; IL-1β, interleukin 1β; NF-κB, nuclear transcription factor kappa B; PPARα, peroxisome proliferator-activated receptor α; RE, response element; TNF-α, tumor necrosis factor-α

Our studies were conducted in mice, and whether *P. loescheii* and butyrate could influence the efficacy and cardiotoxicity of PD-1/PD-L1 inhibitors in humans remains to be determined. Previous studies showed that the enrichment of *Prevotellaceae*, *Rikenellaceae* and *Bacteroides* in the gut microbiota contributes to acute myocardial ischemia in rats [37], and the abundance of *Ruminococcaceae* bacteria is negatively correlated with isoproterenol-induced arterial stiffness [38]. This discrepancy may be due to the differences in the pathological conditions (apoptosis versus arterial stiffness), exogenous toxin (PD-1/PD-L1 inhibitor versus isoproterenol) and the animal models (C57BL/6 mice versus Wistar rats), and future efforts are warranted to clarify these possibilities.

Colonic macrophages provides an active target for potential novel therapies in maintaining homeostasis and resisting inflammation [39]. Macrophages in peritoneal exudate are polarized to an M1 phenotype in PD-1-deficient mice [40]. Our recent study showed that colonic macrophages are polarized to an M1-like phenotype in DOX-induced cardiotoxicity, and reprogramming colonic macrophages away from the M1-like phenotype attenuates DOX-induced acute...
cardiotoxicity [10]. Here, we demonstrated that PD-1/PD-L1 inhibitor-induced gut microbiota dysbiosis and low butyrate production upregulated proinflammatory factors IL-1β and TNF-α in colonic macrophages, and that depleting colonic macrophages or a combination of IL-1β and TNF-α blockade significantly attenuated PD-1/PD-L1 inhibitor-related cardiotoxicity. These data suggest that M1-like colonic macrophages and their proinflammatory factors IL-1β and TNF-α contribute to PD-1/PD-L1 inhibitor-related cardiotoxicity. Given that gut microbiota dysbiosis mediates PD-1/PD-L1 inhibitor-related cardiotoxicity through multiple proinflammatory factors, including IL-1β and TNF-α, novel targeted therapies founded on gut microbiota not only single cytokine, may represent a potential strategy for the prevention of PD-1/PD-L1 inhibitor-related cardiotoxicity.

PPARα, a ligand-activated nuclear receptor, is involved not only in lipid metabolism but also in inflammatory reactions [41]. PPARα inhibits the expression of proinflammatory factors and macrophage M1-like polarization mainly by NF-kB downregulation [30]. Butyrate, one of the natural agonists of PPARα [29], is decreased in M1-like colonic macrophages [10]. In this study, we demonstrated that downregulation of PPARα in colonic macrophages by low butyrate production attenuated its inhibitory effects on NF-kB signaling, and thus upregulated the proinflammatory factors IL-1β and TNF-α. A previous study showed that PPARα activation upregulates human CYP4X1 gene transcription [31], and CYP4X1-derived cannabinoid metabolites further activated PPARα [42]. Consistently, we found that Cyp4x1 knockout inhibited PPARα expression in colonic macrophages, but exogenous supplementation with 14,15-EET-EA promoted PPARα expression in colonic macrophages, but exogenous supplementation with 14,15-EET-EA promoted PPARα expression in the PNMS, thus attenuating PD-1/PD-L1 inhibitor-induced the upregulation of IL-1β and TNF-α. These data suggest that inactivation of the PPARα and CYP4X1-14,15-EET-EA positive feedback loop in colonic macrophages upregulates proinflammatory factors IL-1β and TNF-α, and thereby amplifies PD-1/PD-L1 inhibitor-induced cardiotoxicity.

Although there were important discoveries revealed by this study, some limitations still exist. This study mainly focused on PD-1/PD-L1 inhibitor-associated myocarditis, and other forms of ICI-related cardiotoxicity need to be further investigated. In addition, the mechanism of PD-1/PD-L1 inhibitor-related cardiotoxicity was only investigated in BMS-1-treated mice. Additional experiments with larger sample sizes in anti-PD-1/PD-L1 antibody-treated mice and humans will be performed to validate these results.

Conclusions
Gut microbiota dysbiosis-induced low butyrate production contributes to PD-1/PD-L1 inhibitor-related cardiotoxicity through downregulation of PPARα-CYP4X1 axis in colonic macrophages. Importantly, our study identified the crosstalk between the gut microbiota and colonic macrophages in PD-1/PD-L1 inhibitor-related cardiotoxicity. Our findings propose a novel mechanism of action of PD-1/PD-L1 inhibitor-related cardiotoxicity, and may provide a notable target for making immunotherapy safer and more effective by manipulating the gut microbiota and its metabolite butyrate.

Abbreviations
14,15-EET-EA: 14,15-epoxyeicosatetraenoic acid ethanalamide; ABPAS: Alcian blue-periodic acid-Schiff; Abx: broad-spectrum antibiotic; AST: aspartate aminotransferase; Bax: B-cell lymphoma protein 2-associated X; Bcl-2: B-cell lymphoma-2; BNP: brain natriuretic peptide; CK: creatine kinase; CK-MB: creatine kinase-MB; CM: conditioned medium; CYP4X1: cytochrome P450 4X1; ELISA: enzyme-linked immunosorbent assay; HAV-1: HS-associated protein X-1; HE: Hematoxylin and Eosin; HPLC: high performance liquid chromatography; IL-1β: interleukin 1β; irAEs: immune-related adverse events; LC-MS/MS: liquid chromatographic-tandem mass spectrometry; LDH: lactate dehydrogenase; LEfSe: linear discriminant analysis effect size; NF-kB: nuclear transcription factor kappa B; OligoTUs: Operational Taxonomic Units; PBS: phosphate buffer saline; PCNA: proliferating cell nuclear antigen; PCoA: principal coordinates analysis; PD-1: programmed cell death protein 1; PD-L1: programmed death ligand 1; PNMS: peritoneal macrophages; PPARα: peroxisome proliferator-activated receptor α; P. loescheii: Prevotella loescheii; RE: response element; SCFAs: short-chain fatty acids; SEM: standard error of the mean; TNF-α: tumor necrosis factor-α; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13046-021-02201-4.

Additional file 1.

Acknowledgments
The authors thank the Experimental Teaching Center at the Wuhan University School of Basic Medical Sciences for technical assistance.

Authors’ contributions
YC and YL performed main parts of the experiments, evaluated main parts of the data and wrote the manuscript. YW participated in the evaluation of immunohistochemical results. CW and XC participated in the western blot, PCR and data analysis. XC, XY and LL discussed the experimental setting and financed the study. JY and XZ supervised the study and advised during the manuscript preparation. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China under Grant [82104313 (to Yanzhuo Liu), 82102934 (to Yang Wang), 82073399 and 81872443 (to Jing Yang) and 81970331 (to Xiaoyang Zhou)], and Medical Science Advancement Program (Basic Medical Science) of Wuhan University under Grant [TFX 2018003].

Availability of data and materials
The datasets generated or analyzed during the current study are available on reasonable request.
Declarations

Ethics approval and consent to participate
The animal studies were approved by the Animal Research Committee of Wuhan University and maintained in accordance with the guidelines by the Association for Assessment and Accreditation of Laboratory Animal Care International.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China. 2 Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan 430060, China. 3 Department of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China. 4 Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. 5 Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Received: 22 July 2021   Accepted: 26 November 2021

Published online: 03 January 2022

References
1. Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death −1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy. Pharmacolet Ther. 2019;194:84–106.
2. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. The Lancet Oncology. 2018;19(9):e447–e58.
3. Vannacci C, Galdiero MR, Tocchetti CG. Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology. Circulation. 2017;136(21):1989–92.
4. Rahouma M, Karim NA, Baudou M, Yahia M, Kamil M, Elledissouk I, et al. Cardiac toxicity with immune system targeting drugs: a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Immunotherapy. 2019;11(8):725–35.
5. Tay WT, Fang YH, Beh ST, Liu YW, Hsu LW, Yen CJ, et al. Programmed cell death-1 programmed cell death-ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro. Int J Mol Sci. 2020;21(7).
6. Xia W, Chen H, Chen D, Ye Y, Xie C, Hou M. PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor-related cardiac dysfunction. J Immunother Cancer. 2020;8(2).
7. Ciccarelli M, Dawson D, Falcao-Pires I, Giacca M, Hamdani N, Heymans S, et al. Reciprocal organ interactions during heart failure—a position paper from the ESC working group on myocardial function. Cardiovasc Res. 2019;115(5):854–68.
8. Tocchetti CG, Ameri P, de Boer RA, D’Alessandra Y, Russo M, Sorriento D, et al. KALRN mutations promote antitumor immunity and immunotherapy response in cancer. J Immunother Cancer. 2020;8(2).
9. Li K, Tian H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019;27(3):244–56.
10. Liu SY, Huang WC, Yeh H, Ko CC, Shieh HR, Hung CL, et al. Sequential blockade of PD-1 and PD-L1 causes fulminant cardiotoxicity—from case report to mouse model validation. Cancers (Basel). 2019;11(4).
11. Qiu M, Huang K, Liu Y, Yang Y, Tang H, Liu X, et al. Modulation of intestinal microbiota by glycyrrhizin acid prevents high-fat diet-enhanced pre-metastatic niche formation and metastasis. Mucosal Immunol. 2019;12(4):945–57.
12. Cheng WY, Wu CY, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut. 2020;69(10):1867–76.
13. Hamidzadeh K, Christensen SM, Dalbye E, Chandrasekaran P, Mosser DM. Macrophages and the recovery from acute and chronic inflammation. Front Immunol. 2017;7:567–92.
14. Liu X, Liu Y, Chen X, Wang C, Chen X, Liu W, et al. Multi-walled carbon nanotubes exacerbate doxorubicin-induced cardiotoxicity by altering gut microbiota and pulmonary and colonic macrophage phenotype in mice. Toxicology. 2020;435:152410.
15. Wang C, Li Y, Chen H, Huang K, Liu X, Qiu M, et al. CYP4X1 inhibition by flavonoid CH625 normalizes glioma vasculature through reprogramming TAMs via CEBB and EGFR-STAT3 axis. J Pharmacol Exp Ther. 2018;365(1):72–83.
16. Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer, lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39.
17. Liu M, Ma Y, Zhong Y, Liu Q, Chen C, Qiang L, et al. KARIN mutations promote antitumor immunity and immunotherapy response in cancer. J Immunother Cancer. 2020;8(2).
18. Li K, Tian H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019;27(3):244–56.
19. Liu SY, Huang WC, Yeh H, Ko CC, Shieh HR, Hung CL, et al. Sequential blockade of PD-1 and PD-L1 causes fulminant cardiotoxicity—from case report to mouse model validation. Cancers (Basel). 2019;11(4).
20. Qiu M, Huang K, Liu Y, Yang Y, Tang H, Liu X, et al. Modulation of intestinal microbiota by glycyrrhizin acid prevents high-fat diet-enhanced pre-metastatic niche formation and metastasis. Mucosal Immunol. 2019;12(4):945–57.
21. Vladoumiou M, Bassaganya-Riera J, Tubau-Juni N, Kronsteiner B, Leber A, Philipson CW, et al. Cooperation of gastric mononuclear phagocytes with helicobacter pylori during colonization. J Immunol. 2017;198(8):3195–204.
22. Zhou X, Cao L, Jiang C, Xie Y, Cheng X, Krausz KW, et al. PPARalpha-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nat Commun. 2014;5:4573.
23. Wang C, Li Y, Chen H, Zhang J, Zhang J, Qin T, et al. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma. Cancer Lett. 2017;402:131–41.
24. Erawijantari PP, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, et al. Influence of gastrectomy for gastric cancer treatment on faecal microbiome and metabolite profiles. Gut. 2020;69(8):1404–15.
25. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.
26. Hu JR, Nlondi R, Lipson EJ, Naidoo J, Ardheil R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854–68.
27. Vlakova M, Vlasek J, Sorof J, Sverdlikov J, Simeonova E, Dambrova M, et al. Microbiota-derived metabolite trimethylamine N-oxide protects mitochondrial energy metabolism and cardiac functionality in a rat model of right ventricle heart failure. Front Cell Dev Biol. 2020;8:2741.
28. Hao G, Wen J, Hu JL, Nie QX, Chen HH, Xiong T, et al. Polysaccharide from fermented Morromoracia charantia L. with lactobacillus plantarum NC116 ameliorates type 2 diabetes in rats. Carbohydr Polym. 2018;201:624–33.
29. Oh HYP, Visvalingam V, Wahl W. The PPAR-microbiota-metabolic organ trilogy to fine-tune physiology. FASEB J. 2019;33(9):9706–30.
30. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action. J Pharmacol Exp Ther. 2019;370(1):94–107.
31. Russo M, Guida F, Paparo L, Trinchese G, Atiroo R, Avagliano C, et al. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity. Eur J Heart Fail. 2019;21(4):519–28.
32. Wang G, Sun S, Wu X, Yang S, Wu Y, Zhao J, et al. Intestinal environmental conditions associated with the tissue damages induced by perfluorooctane sulfonate exposure. Ecotoxicol Environ Saf. 2020;197:110590.
33. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391.
34. Brandsma E, Kloosterhuis NJ, Koster M, Dekker DC, Gijbels MJJ, van der Velden S, et al. A proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis. Circ Res. 2019;124(1):94–100.
35. Flannigan KL, Taylor MR, Pereira SK, Rodriguez-Argüello J, Moffat AW, Alston L, et al. An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil. J Heart Lung Transplant. 2018;37(9):1047–59.
36. Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, et al. The gut microbiome is associated with clinical response to anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res. 2020;8(10):1251–61.
37. Sun L, Jia H, Li J, Yu M, Yang Y, Tian D, et al. Cecal gut microbiota and metabolites might contribute to the severity of acute myocardial ischemia by impacting the intestinal permeability, oxidative stress, and energy metabolism. Front Microbiol. 2019;10:1745.
38. Menni C, Lin C, Cecelja M, Mangino M, Matey-Hernandez ML, Keehn L, et al. Gut microbial diversity is associated with lower arterial stiffness in women. Eur Heart J. 2018;39(23):2390–7.
39. Bain CC, Schridde A. Origin, differentiation, and function of intestinal macrophages. Front Immunol. 2018;9:2733.
40. Chen W, Wang J, Jia L, Liu J, Tian Y. Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan. Cell Death Dis. 2016;7:e2115.
41. Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, et al. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocr Rev. 2018;39(5):760–802.
42. O’Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173(2):1899–910.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions